A carregar...
Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease
Imatinib is a promising candidate for the treatment of fibrotic diseases. This retrospective study evaluated the use of imatinib for the treatment of refractory sclerotic chronic graft-versus-host disease in 14 patients with different hematologic malignancies. Imatinib was started at a median of 44...
Na minha lista:
| Publicado no: | Blood |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5162701/ https://ncbi.nlm.nih.gov/pubmed/19289852 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-02-204750 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|